Articles tagged with Vaccination
A vaccine has been shown to delay symptoms of prion brain disease in mice by inducing an immune response and producing antibodies. This breakthrough could potentially lead to a therapeutic response and prevent the disease in animals at risk.
The company's phase I clinical trial will examine NicVAX's safety and ability to stimulate the immune system in nonsmokers. If successful, additional trials will be conducted to investigate its efficacy in smokers and ex-smokers.
Tumor vaccines via dendritic cells aim to enhance the immune response against cancer cells Researchers found that dendritic cells can stimulate the production of antibodies and T-cells specific to cancer antigens
A multi centre collaborative study found a two-thirds reduction in group C meningococci carriage after UK-wide vaccination. The programme protected both vaccinated and unvaccinated populations, providing valuable insights for future comprehensive vaccines.
Researchers have developed a new TB vaccine by fusing a Mycobacterium tuberculosis antigen with a gene that highly expresses a thiol-specific-antioxidant protein from Leishmania major. This hybrid DNA vaccine increased protein production, leading to a more robust immune response in mice.
Emory University is conducting a clinical trial to evaluate an improved anthrax vaccine regimen with reduced injections and muscle administration. The study will enroll 1,560 volunteers across six sites and aim to simplify the existing dosing schedule while providing more data on safety.
A study by Kansas State University researchers has linked anthrax vaccination to poor health outcomes in Gulf War veterans, suggesting that the combination of vaccinations and medications may have adverse effects on susceptible individuals. The research also found that falsified or destroyed medical records made it difficult to assess ...
A recent study found that people previously infected with HCV are 12 times less likely to develop persistent infection than those infected for the first time. This suggests that immunity can be acquired to protect against viral persistence, making vaccines a potential solution to reduce medical consequences of HCV infection.
Fox Chase Cancer Center researcher Glenn F. Rall is studying whether a link exists between the measles vaccine and the development of autism. He believes that maternal exposure history to measles may afford protection to offspring, but more research is needed.
A new vaccine targeting ticks' gut wall could significantly reduce their fertility and larval survival, decreasing the risk of diseases like Lyme disease and tick-borne encephalitis. The development comes as tick-borne diseases are increasing in the UK and becoming more prevalent globally.
University of Rhode Island researchers, Thomas Mather and David Nelson, are developing a new Lyme disease vaccine using tick saliva genes. They have received $2.3 million NIH grant to identify promising genes over five years.
A new NIAID study found that diluting smallpox vaccine can expand the US vaccine supply fivefold, providing more protection against a potential outbreak. The trial used a freeze-dried live vaccinia virus vaccine and resulted in high take rates with minimal side effects.
Researchers have developed a potent antiviral drug, HDP-CDV, that can block the replication of variola and orthopox viruses, including smallpox. The oral drug is 100 times more active than existing cidofovir and may be used to treat and prevent smallpox infections.
Researchers at Virginia Tech will develop plant-expressed antigens and adjuvants to create affordable, effective vaccines. The goal is to produce inexpensive, disease-fighting vaccines through plant-based delivery systems.
A new peptide-based vaccine has been shown to reduce arterial plaque formation by 60-70% in mice with high cholesterol levels, according to a study led by Cedars-Sinai's P.K. Shah and the Swedish team of Gunilla Nordick-Fredricksson. The vaccine targets the major protein component of low-density lipoprotein (LDL) cholesterol.
A new study shows that a vaccine based on a chimpanzee adenovirus possesses the immunological strengths of a human adenovirus vaccine without its drawbacks. The vaccine, developed by researchers at The Wistar Institute, has been shown to be effective in mice against rabies and other viruses.
A new protocol for administering pneumonia vaccines has shown promising results in improving vaccination rates among hospital patients. The study found that the protocol resulted in a 38% vaccination rate, compared to 4.9% in standard procedures. This intervention can potentially save lives and reduce healthcare costs.
A recent outbreak in England and Wales highlights the need for better vaccination coverage among Mecca pilgrims, with a previously rare strain causing high case-fatality rates. Enhanced surveillance and early recognition are crucial to prevent further transmission of the disease.
The Nabi experimental vaccine reduced bloodstream infections caused by Staphylococcus aureus in end-stage kidney disease patients by nearly 60%. The vaccine elicited a significant antibody response in 86% of the patients, and significantly reduced the incidence of systemic S. aureus infection in the blood.
Researchers at the University of Melbourne have developed a potential allergy vaccine using a modified rye grass protein that reduces allergenic response while boosting immune system. The vaccine, delivered in its pure form, may significantly reduce risk of anaphylactic shock and increase immunotherapy efficacy.
A new prostate cancer vaccine developed at Duke University Medical Center has shown promising results, boosting the patient's immune system to fight cancer. The vaccine, made from the patient's own dendritic cells, causes no adverse side effects and activates T cell responses against tumor cells.
A study conducted by Yale University has shown that a cocaine vaccine can significantly reduce cravings and addiction in patients who abuse the drug. The vaccine was found to be safe and effective in increasing anti-cocaine antibodies, which help prevent the uptake of cocaine across the blood-brain barrier.
A recent study found that infants can generate protective immune responses to multiple vaccines simultaneously, using only a small percentage of their immune system. Current research also shows that vaccine formulations have been refined to contain fewer antigens, reducing the risk of overwhelming the infant's immune system.
Researchers at UT Southwestern Medical Center have developed a new procedure for delivering vaccines by manipulating dendritic cells in the skin, reducing production time from 10 days to just 24 hours. This breakthrough could lead to more effective cancer treatments and broader clinical applications.
A recent yellow fever outbreak in Guinea highlights insufficient international stocks of the 17D yellow fever vaccine, which can protect for at least 10 years. WHO recommends an emergency stockpile of 1 million doses to provide a rapid response to large outbreaks.
The US government is investing in bioterrorism research through seven new initiatives, aiming to develop vaccines and treatments for diseases like anthrax and smallpox. The initiatives will also support basic research and partnerships between academia, industry, and government.
A genetic vaccine developed by the University of Nebraska Medical Center has shown promising results in mice studies, combining DNA and adenovirus to deliver a tumor suppressor factor. The vaccine improved survival rates up to 40% in mice with metastatic breast cancer.
Researchers have found that a Japanese encephalitis (JE) vaccine may also protect people from the most serious complication associated with West Nile virus infection. The study tested two vaccines in hamsters and found that they provided better protection than other options, including a yellow fever vaccine.
Researchers aim to better understand cellular immunity in fighting Alzheimer's disease using a new mouse model jointly developed by USF and the University of Pennsylvania.
Researchers at Ohio State University have developed a new DNA-based vaccine approach that successfully immunizes mice against anthrax. The vaccine uses combinations of two gene products produced by the bacteria responsible for causing anthrax, resulting in strong immune responses.
A recent study suggests that the rotavirus vaccine did not increase the risk of intussusception, a rare bowel blockage, in infants under 1 year old. The study found a 4-10% decline in hospitalizations for intussusception during the period when the vaccine was available.
A recent study found that Rotashield may trigger intussusception events in susceptible infants, but these risks are compensated for by a lower risk of intussusception later in infancy. The study analyzed hospital admissions of infants with intussusception in ten US states during the period when Rotashield was in use.
Researchers are exploring postraumatic vaccination as a potential treatment for spinal cord injuries, showing promise in promoting neural regeneration and recovery. Early studies suggest that this approach may improve functional outcomes and quality of life for affected individuals.
Researchers at The Scripps Research Institute have solved the structure of a neutralizing antibody against HIV, marking an important milestone in the development of an effective vaccine. This breakthrough demonstrates that the human immune system can produce antibodies effective against HIV and provides a template for vaccine design.
Researchers at NYU Langone Health successfully immunized mice against Alzheimer's disease using a new vaccine that reduces amyloid plaque and soluble beta levels. The vaccine, modeled on a modified peptide, appears to be non-toxic and shows great promise for the treatment of Alzheimer's disease.
A program called Operation Stop Cough reduced illness rates by 45% among Navy recruits who were ordered to wash their hands frequently. Handwashing may be especially valuable during the respiratory disease season, as it can prevent less virulent illnesses and mitigate outbreaks.
A new model for detecting early meningitis epidemics in sub-Saharan Africa has been developed, using weekly incidence thresholds to identify outbreaks. The model uses clinic-based weekly incidence of 5-10 cases per 100,000 inhabitants to detect all meningitis epidemics with high sensitivity.
Dr. Tramont takes helm of DAIDS, a successful program critical to understanding HIV causes and creating antiretroviral drugs, with a focus on building on its legacy
Two fatal cases of haemorrhagic fever associated with yellow fever 17DD substrain vaccine were reported in Brazil, highlighting the need to review the vaccine's safety. The cases led Philippe Marianneau and colleagues from Institut Pasteur to emphasize the importance of investigating mechanisms of attenuation of yellow-fever virus.
The Office of Naval Research has funded a study to develop new plasmid DNA vaccines for marine mammals, aiming to prevent epidemic disease. The studies may soon allow for better protection against infection using vaccination of individual animals within a population.
Researchers developed a rapid ELISPOT assay to detect T cells responding to ESAT-6 protein, which is absent in BCG vaccine strains. The new test shows stronger correlation with exposure intensity than existing tuberculin skin test (TST), providing potential for improved tuberculosis control and targeted preventative therapy.
A study found that individuals with high scores for neuroticism tend to have lower immune system responses to vaccination, making them more vulnerable to disease. Stress can further weaken the immune system, exacerbating this effect.
A new pancreatic cancer vaccine has been found to be safe and successful in reaching immune system cells, with several patients remaining disease-free over 30 months after diagnosis. The vaccine uses lab-grown pancreatic cancer cells genetically-modified with the immune-boosting gene GM-CSF.
A study found that children with personal exemptions from immunization are 22.2 times more likely to acquire measles and 5.9 times more likely to acquire pertussis than vaccinated children. Exemptions also increase community risk, particularly in schools with outbreaks.
Scientists have discovered a vaccine that may prevent and treat Alzheimer's by blocking the production of toxic amyloid ß peptides, which accumulate in the brain and cause dementia. The vaccine has shown promise in removing amyloid plaques and preventing learning impairment in transgenic mice, paving the way for potential human trials.
Research by Imperial College scientists shows that previous infection history greatly affects the duration and severity of subsequent lung infections. This highlights the importance of considering past infections in vaccine design, particularly for individuals with varying ages and immune systems.
Short-term travelers to high-risk areas are at risk of getting typhoid fever, particularly those visiting India and Pakistan. The CDC recommends vaccination for travelers who have prolonged exposure to contaminated food and drink.
The phase III clinical trial demonstrated a significant reduction in S. aureus bacteremias during the first ten months, but not after one-year follow-up. The study found that StaphVAX-induced antibodies protected against bloodstream infections.
The Sequella Global Tuberculosis Foundation invites researchers worldwide to apply for $50,000 grants to develop effective vaccines for human tuberculosis. The program aims to spur innovation and encourage new approaches to vaccine development.
Researchers at Duke University Medical Center and Geron Corp. have made promising findings on a 'universal' cancer vaccine based on the telomerase protein. The active part of telomerase can stimulate development of immune cells that recognize and kill multiple, unrelated mouse and human cancer cells.
Research on a monkey vaccine for anthrax suggests that while vaccinated individuals may survive an attack, they could become severely ill, posing a burden on the military. The US Army Medical Research Institute's 1991 test found that monkeys given the vaccine became sick for up to two weeks after inhaling anthrax spores.
A plant-based vaccine has successfully triggered human immunity to the Norwalk virus, causing widespread food-borne illness in the US. Researchers at Cornell University and the University of Maryland have developed a transgenic potato vaccine that shows promising results in clinical trials.
Researchers are testing two vaccines, using vaccinia and fowlpox viruses, to treat prostate cancer that has spread beyond the gland. The goal is to boost the patient's immune system and eliminate cancer cells before they become symptomatic.
The study confirms that M-Vax increases the survival rate of patients with advanced Stage III melanoma, even after disease recurrence. Patients who developed an immune response against their melanoma had a far better outcome, with a five-year survival rate of 65%.
The data from an ongoing Phase 1/2 trial of O-Vax in patients with advanced ovarian cancer indicates that the vaccine induces a positive immunological response, as measured by a delayed type hypersensitivity test. Favorable clinical responses were also observed, including complete regression of tumors and normalization of CA-125 levels.
A custom-made vaccine created from a patient's own cancer tumor cells has proven effective in prolonging the survival of patients with malignant melanoma. The vaccine resulted in a 47% five-year survival rate among 214 patients with disease spread, outperforming standard treatment.
New York State-based study finds that removing financial barriers through vaccine-financing reforms reduces scattered care and underimmunization among disadvantaged children. The reforms appear effective in keeping children in their primary care medical homes.
Mothers prefer family practice vaccinations over clinics, citing lack of empathy and pain from vaccination as reasons. Health professionals who acknowledge distress and engage with babies are valued most by mothers, research suggests.
Researchers have developed a method to modify an allergen, like ragweed, into a vaccine that induces protective molecules, type 1 helper T cells (Th1), inhibiting the allergic inflammatory reaction. The new vaccine, named AIC, was found to be 180 times less allergenic than a licensed product in human studies.
Researchers used genomics-based approach to discover new surface proteins that behave differently and are present across multiple strains of Neisseria meningitidis. These proteins can stimulate an antibody response capable of killing the bacterium, a key property for vaccine efficacy.